Fluoroquinolones resistant Gram-positive cocci isolated from University of Calabar Teaching Hospital, Nigeria

Augustine A. Unimke; Iniobong E. Andy

doi:10.30574/gscbps.2017.1.1.0003

Authors

Augustine A. Unimke Department of Microbiology, Faculty of Biological Sciences, University of Calabar, PMB 1115, Calabar, Cross River State, Nigeria.
Iniobong E. Andy Department of Microbiology, Faculty of Biological Sciences, University of Calabar, PMB 1115, Calabar, Cross River State, Nigeria.

DOI:

https://doi.org/10.30574/gscbps.2017.1.1.0003

Keywords:

Fluoroquinolones, Gram-positive cocci, Antibiotic resistance, Staphylococcus; Streptococcus

Abstract

Eighty four clinical samples of Gram-positive cocci isolated from University of Calabar Teaching Hospital, Nigeria were examined for resistance to fluoroquinolones antibiotics using disc diffusion method on Muller Hinton agar. Forty four of the total isolates were Staphylococcus spp. while forty isolates were Streptococcus spp. Resistance rates were highest against ofloxacin 18 (41%) for Staphylococcus spp. and 10 (25%) for Streptococcus spp. followed by sparfloxacin 15 (34%) and 6 (15%) for Staphylococcus spp. and Streptococcus spp., respectively; while resistance to ciprofloxacin was the least 14 (32%) and 4 (10%) for Staphylococcus spp. and Streptococcus spp., respectively. These findings highlight the development of resistance by Gram-positive cocci to fluoroquinolones and suggest for the careful and appropriate administration of these agents as well as infection-control practices.

Metrics

Metrics Loading ...

References

Bisno AL. (2004). Medical Progress: Group A Streptococcal infections and acute rheumatic fever. New England Journal of Medicine, 325, 783-793.

Woodford NA. (2007). Biological counterstrike: Antibiotic resistance mechanisms of Gram– positive cocci. Journal of Infections and Health Protection, 12, 1123-1142.

Foster TJ. (2006). Potential for vaccination against infections caused by Staphylococcus aureus. Vaccine, 9, 221-228.

Hooper DC. (2000). New use for new and old fluoroquinolones and the challenges of resistance. Clinical Infectious Diseases, 30, 24-32.

Blondeau JM. (2009). Expanded activity and utility of the new fluoroquinolones. A Review of Clinical Therapy, 21, 3-7.

Franklin DL. (2003). Antimicrobial Resistance: the example of Staphylococcus aureus. Journal of Clinical Investigations, 9, 1265-1273.

DIFCO (1984). Dehydrated culture media and reagents for microbiology (10th ed). Difco laboratories, Michigan.

Mark HB, Beers MD and Berkow R. (2009). Antibacterial Drugs: Fluoroquinolones. The Merck Manual of Diagnosis and Therapy, 13, 153-174.

Lipsky BA. (2000). Fluoroquinolones toxicity profiles. A review focusing on newer agents. Clinical Infectious Diseases, 28, 352.

Yagupsky P. (2009). Selection of antibiotic–resistant pathogens in the community. Pediatric Infectious Disease Journal, 25, 974-976.

Bhakdi SE and Tranum JJ. (2011). Alpha-toxin of Staphylococcus aureus. Microbial Reviews, 55, 733-741.

Cambau ET. (2003). Mechanism of resistance to quinolones. Drugs, 45 (3), 15-19.

Holt JG, Krieg NR, Senath PHA, Staley JT and Williams ST. (1994). Bergey’s manual of determinative bacteriology. (9th ed).Williams and Wilkins, Baltimore.

Walker RC. (2011). The fluoroquinolones. Mayo Clinical Procedures, 74, 1030.

McCracken GE. (2014). Emergence of resistant Streptococcus pneumonia: A problem in pediatrics. Pediatric Infectious Disease Journal, 14, 424 - 428.

Giamarellou H. (2011). Activity of quinolones against Gram–positive cocci: Clinical features. Drug, 49 (2), 58-70.

Kollef MH. (2007). Bugging the bugs: Novel approaches in the strategic management of resistant Staphylococcus aureus infections. Clinical Infectious Diseases, 45 (3), 163-164.